NCT02917993 2026-02-09An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerIncyte CorporationPhase 1/2 Completed59 enrolled
NCT02265510 2020-04-17An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated83 enrolled 31 charts